Massachusetts is currently home to 3208 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
Recruiting
A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols. The specific hypotheses include: * Ga-PSMA PET/MRI may allow robust and reproducible noninvasive in vivo quantitation of hepatic macro and microhemodynamics in cirrhotic patients * Dedicated simultaneously acquired DWI sequences might quantitate liver fibrosis and improve hemodynamic quantitation. * Ga-PSMA PET/MRI may allow noninvasiv... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/09/2024
Locations: Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts
Conditions: Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
MOLAR: Mapping Oral Health and Local Area Resources
Recruiting
The goal of this clinical trial is to test the impact of a screening and linkage intervention for adverse social determinants of health (aSDoH) on oral health linkage to care for emergency department patients. Researchers will compare three groups: Patients in Arm A will receive paper handouts with general oral health and aSDoH resources. Patients in Arm B will receive paper handouts with geographically-proximate oral health and aSDoH resources. Patients in Arm C will receive geographically-prox... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
02/09/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Dental Diseases
Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
Recruiting
The goal of the study is to examine multiple markers of anthropometrics, body composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry (DXA) output, which is considered the current clinical gold-standard tool to measure body composition. The result of this study will provide detailed data regarding the nutrition and body composition within this Cystic Fibrosis population and also provide a baseline evaluation for use of these biomarkers in the future studies inclu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Massachusetts General Hospital (MGH), Boston, Massachusetts
Conditions: Cystic Fibrosis
Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.
Recruiting
In this study twenty-five (25) subjects with Crohn's disease scheduled for possible surgical intervention will be recruited for this study and a PET/MR scan using the collagen-binding radiotracer will be performed. The study aims to establish the performance figures of PET/MR using \[68Ga\]CBP8-PET for preoperative detection and differentiation of strictures with a fibrotic component in patients with Crohn's disease by using surgical and histologic findings (when available) as the standard for c... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/08/2024
Locations: Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts
Conditions: Crohn Disease
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Recruiting
This study will evaluate the effectiveness of skin cooling in increasing tolerability of four treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 980nm laser, a 755nm laser, radio-frequency injection, and a Kybella injection. Each patient will have a treatment and a control site..
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/07/2024
Locations: Wellman Center for Photomedicine, Boston, Massachusetts
Conditions: Neurofibromatosis 1
Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation
Recruiting
The aim of this study is to better understand how tenapanor affects the metagenomics and metabolomics of patients with irritable bowel syndrome with constipation (IBS-C). Tenapanor is the newest FDA-approved agent for IBS-C. It is a small molecule that inhibits the NHE3 receptor, leading to impaired sodium and water absorption in the intestine. Previous clinical trials comparing tenapanor to placebo showed that a 50 mg dose of tenapanor led to increased bowel movements and decreased abdominal pa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/07/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: IBS, IBS - Irritable Bowel Syndrome
fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
Recruiting
Evaluation of neuroplasticity of pain pathways and corneal afferent nerve regeneration following corneal crosslinking (CXL) in keratoconus patients using fMRI and corneal In Vivo Confocal Microscopy (IVCM).
Gender:
ALL
Ages:
Between 8 years and 35 years
Trial Updated:
02/07/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Pain, Postoperative, Pain, Chronic, Pain, Acute, Surgical Injury, Surgical Wound, Cornea Injury, Cornea, Keratoconus
Strength After Breast Cancer
Recruiting
The goal of this study is to explore whether a group exercise program called Strength After Breast Cancer can be delivered in an outpatient physical therapy clinic to improve physical function among women after treatment for breast cancer. The main questions this study aims to answer are: * Can the Strength After Breast Cancer program and the associated outcome battery be successfully delivered in an outpatient physical therapy clinic at Massachusetts General Hospital and do participants find... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: MGH Institute of Health Professions, Boston, Massachusetts
Conditions: Breast Cancer
Interstage Monitoring Using an Implantable Loop Recorder: A Pilot Study
Recruiting
The primary objective of this investigation is to evaluate the feasibility and safety of implantable loop recorder implantation (using the LUX-DX™) in newborns undergoing stage 1 palliation. The secondary objective of the investigation is to evaluate the feasibility of continuous measurement of heart rate and arrhythmia using an implantable loop recorder (LUX-Dx™) during the interstage period. An implantable loop recorder will be placed at the time of chest closure following stage 1 palliation... Read More
Gender:
ALL
Ages:
30 days and below
Trial Updated:
02/06/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Univentricular Heart
BostonGene-Integrated Genomic Registry (BIGR)
Recruiting
The purpose of this project is to develop a comprehensive database of genomic, transcriptomic, molecular, and clinical characteristics of oncology patients to discover, define, and develop genomic and transcriptomic markers to improve future clinical outcomes across cancer types
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: BostonGene, Waltham, Massachusetts
Conditions: Malignancy
Anamorelin Study for Advanced Pancreatic Cancer
Recruiting
Multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 100 subjects with advanced PDAC and cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 25 weeks. Subjects will be instructed to take the study drug at least 1 hour before their first meal of the day
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Lahey Hospital & Medical Center, Burlington, Massachusetts
Conditions: Metastatic Pancreatic Cancer
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Recruiting
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/06/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: CLL/SLL